Company

ImmunoPrecise is a full-service, therapeutic antibody discovery company offering species agnostic advancements such as the B cell Select™ single-cell interrogation technology, DeepDisplay™ custom phage libraries, as well as the Abthena™ bispecific program- platforms that blend seamlessly with IPA’s Artemis Intelligence Metadata (AIM)™ capabilities to enable rapid turnaround on additional algorithmic outputs in therapeutic optimization, stability, affinity and manufacturability.

IPA is focused on the next generation of antibody discovery, to deliver the most therapeutically relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials. With over 25 years of experience in the custom antibody business, ImmunoPrecise provides high customer satisfaction through a customized, professional approach.

ImmunoPrecise discovery and development are conducted in Utrecht and Oss, the Netherlands (U-Protein Express and IPA Europe, respectively), and in Victoria, British Columbia (IPA Canada). The Company operates globally to offer a continuum of superior antibody services, transforming the face of therapeutic discovery, by decreasing turnaround time and risk, and promoting clinical success.

ImmunoPrecise’s research and development scientists pride themselves in high customer satisfaction and our clients have grown accustomed to receiving our thorough and professional service. We customize every project to generate antibodies that meet your specific needs.

Management Team

Jennifer Bath, Ph.D.

Chief Executive Officer and President

View Bio

Jennifer Bath is the CEO and President of ImmunoPrecise Antibodies. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry, with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.

Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. Here, she headed the global sales and client relations teams, and defined business strategies by applying knowledge based on the science, technology and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.

Lisa Helbling

Chief Financial Officer

View Bio

Lisa Helbling serves as the Chief Financial Officer for ImmunoPrecise Antibodies. At ImmunoPrecise, she oversees financial and strategic management, including the company’s financial reporting and long-range business planning. Additionally, she supervises human resources and legal. She brings over thirty years of broad experience in accounting, finance, enterprise risk management, audit, and ESOPs. Currently, she serves on the board of directors for Healthy Dakota Mutual Holdings and Blue Cross Blue Shield of North Dakota and is the Chair of the Audit & Compliance Committee. Prior to joining the executive team, Ms. Helbling served as CFO at Anchor Ingredients and TMI Hospitality, as well as VP of Internal Audit and Business Risk Management at Otter Tail Corporation.

Dr. Stefan Lang

Chief Business Officer

View Bio

Dr. Stefan Lang joined ImmunoPrecise in October 2019 as the Chief Business Officer. He is responsible for corporate and business development initiatives, as well as corporate and product strategic planning. He holds a Dr. rer. nat. in biology from the Technical University Karlsruhe, Germany, and a diploma in biology from the University of Kassel, Germany. He started his career as a technical consultant and moved into the biotech industry in 2000.

Dr. Lang has an impressive breadth of leadership within the biotech industry, including experience working at the organizational level and as a globally-recognized and respected leader in antibody business development.

In his most recent role, Dr. Lang worked in an executive role at Aldevron LLC, as the Vice President of Business Development, with his main focus on corporate strategy, R&D innovation, sales and business development. Prior to Aldevron, he worked at GENOVAC, a pioneer in genetic immunization for antibody generation.

Chip Wheelock

Chief Technology Officer

View Bio

As the Chief Technology Officer of ImmunoPrecise Antibodies, Chip Wheelock is responsible for overseeing information technology aspects of the company. Mr. Wheelock works closely with the other members of the Executive Management team, and unit business leaders, to grow the company through the use of software and technology services.

Mr. Wheelock brings a diverse background to ImmunoPrecise. He has held leadership positions within the software development and services industries over the past 25 years. His responsibilities encompassed global ERP deployments, cloud transformations and building a strategic line of business applications. Mr. Wheelock’s experience includes 16 years at Microsoft in various roles, and drove strategic and technical initiatives for many large organizations. Chip holds a bachelor’s degree from the University of Kansas along with several industry and project management certifications.

Kari Graber

VP of Client Relations and Project Management

View Bio

Kari Graber serves as the Vice President of Client Relations and Project Management for ImmunoPrecise Antibodies, and is responsible for the overall leadership and implementation of the Project Management program throughout ImmunoPrecise’s global family of companies. She has over 20 years of experience in developing, implementing and directing laboratory operations, quality assurance, regulatory compliance, and supply chain management programs for various food manufacturers, and spent five years as Sales and Technical Director for a pasteurization/sterilization technology and equipment supplier. Prior to joining ImmunoPrecise, Ms. Graber served at Aldevron LLC, where she held a client relations management role for their antibody services platform. She holds a Bachelor of Science in Food Science & Technology and a Minor in Microbiology.

Jason Orloske

VP of Operations

View Bio

Jason Orloske serves as the Vice President of Operations for ImmunoPrecise, and is responsible for operationalizing strategic initiatives and helping drive growth. Mr. Orloske is a transformational business leader with 20 years’ experience in project portfolio management and strategic delivery. He partners with IPA management to initiate, plan, design, monitor and control global projects, while ensuring they align with ImmunoPrecise’s vision.

Mr. Orloske brings a diverse background to ImmunoPrecise. Most recently, he led implementation management at WEX Health (health benefits SaaS platform), and Aldevron LLC, where he headed the North Dakota project management office. He holds a master’s degree in Project Management.

Dr. Debby Kruijsen

General Manager, Immunoprecise Antibodies Europe

View Bio

Dr. Debby Kruijsen is the General Manager of ImmunoPrecise Antibodies Europe, formerly ModiQuest Research (Oss, The Netherlands), which became part of the ImmunoPrecise family of companies in April 2018.

She began her career in immunology at Utrecht University in the Netherlands. In 2012, she joined ModiQuest Research where she held different scientific and management positions until she became General Manager of ImmunoPrecise Antibodies Europe. Dr. Kruijsen works closely with the executive and global teams to develop and execute business strategies, improve operational efficiencies, and support ImmunoPrecise as an innovative company in the CRO space.

Teri Otto

General Manager, Immunoprecise Antibodies Canada

View Bio

Teri Otto is the General Manager of ImmunoPrecise Antibodies Canada (Victoria, BC). She works closely with the executive and internal teams to implement best practices and company strategy. Ms. Otto has held a variety of scientific and management positions prior to her role as General Manager.

Teri holds a Bachelor of Science in Microbiology and Associate degrees in Psychology and Applied Chemistry/Biochemistry.

Dr. Martin Hessing

General Manager, U-Protein Express

View Bio

Dr. Martin Hessing is the General Manager and co-founder of U-Protein Express (Utrecht, The Netherlands), which became part of the ImmunoPrecise family of companies in September 2017. He has a background in Biochemistry and Hematology-Immunology from Utrecht University and held postdoc positions at Kyushu University, in Japan, and Sanquin, in Amsterdam. He obtained work and management experience at the TNO-Nutrition and Food Research Institute as well as at Organon Teknika (now Biomerieux). In 2000, he co-founded AM-Pharma BV, a biopharmaceutical company specializing in anti-infectives and sepsis. In addition, Dr. Hessing was co-founder of BiOrion BV, Microdish, SERPINx and U-PACT, and served in a number of other biotech start-up companies in various roles. He is co-author of over 50 peer-reviewed papers and seven patent applications.

Jennifer Bath, Ph.D.

Chief Executive Officer and President

View Bio

Jennifer Bath is the CEO and President of ImmunoPrecise Antibodies. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry, with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.

Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. Here, she headed the global sales and client relations teams, and defined business strategies by applying knowledge based on the science, technology and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.

Lisa Helbling

Chief Financial Officer

View Bio

Lisa Helbling serves as the Chief Financial Officer for ImmunoPrecise Antibodies. At ImmunoPrecise, she oversees financial and strategic management, including the company’s financial reporting and long-range business planning. Additionally, she supervises human resources and legal. She brings over thirty years of broad experience in accounting, finance, enterprise risk management, audit, and ESOPs. Currently, she serves on the board of directors for Healthy Dakota Mutual Holdings and Blue Cross Blue Shield of North Dakota and is the Chair of the Audit & Compliance Committee. Prior to joining the executive team, Ms. Helbling served as CFO at Anchor Ingredients and TMI Hospitality, as well as VP of Internal Audit and Business Risk Management at Otter Tail Corporation.

Dr. Stefan Lang

Chief Business Officer

View Bio

Dr. Stefan Lang joined ImmunoPrecise in October 2019 as the Chief Business Officer. He is responsible for corporate and business development initiatives, as well as corporate and product strategic planning. He holds a Dr. rer. nat. in biology from the Technical University Karlsruhe, Germany, and a diploma in biology from the University of Kassel, Germany. He started his career as a technical consultant and moved into the biotech industry in 2000.

Dr. Lang has an impressive breadth of leadership within the biotech industry, including experience working at the organizational level and as a globally-recognized and respected leader in antibody business development.

In his most recent role, Dr. Lang worked in an executive role at Aldevron LLC, as the Vice President of Business Development, with his main focus on corporate strategy, R&D innovation, sales and business development. Prior to Aldevron, he worked at GENOVAC, a pioneer in genetic immunization for antibody generation.

Chip Wheelock

Chief Technology Officer

View Bio

As the Chief Technology Officer of ImmunoPrecise Antibodies, Chip Wheelock is responsible for overseeing information technology aspects of the company. Mr. Wheelock works closely with the other members of the Executive Management team, and unit business leaders, to grow the company through the use of software and technology services.

Mr. Wheelock brings a diverse background to ImmunoPrecise. He has held leadership positions within the software development and services industries over the past 25 years. His responsibilities encompassed global ERP deployments, cloud transformations and building a strategic line of business applications. Mr. Wheelock’s experience includes 16 years at Microsoft in various roles, and drove strategic and technical initiatives for many large organizations. Chip holds a bachelor’s degree from the University of Kansas along with several industry and project management certifications.

Kari Graber

VP of Client Relations and Project Management

View Bio

Kari Graber serves as the Vice President of Client Relations and Project Management for ImmunoPrecise Antibodies, and is responsible for the overall leadership and implementation of the Project Management program throughout ImmunoPrecise’s global family of companies. She has over 20 years of experience in developing, implementing and directing laboratory operations, quality assurance, regulatory compliance, and supply chain management programs for various food manufacturers, and spent five years as Sales and Technical Director for a pasteurization/sterilization technology and equipment supplier. Prior to joining ImmunoPrecise, Ms. Graber served at Aldevron LLC, where she held a client relations management role for their antibody services platform. She holds a Bachelor of Science in Food Science & Technology and a Minor in Microbiology.

Jason Orloske

VP of Operations

View Bio

Jason Orloske serves as the Vice President of Operations for ImmunoPrecise, and is responsible for operationalizing strategic initiatives and helping drive growth. Mr. Orloske is a transformational business leader with 20 years’ experience in project portfolio management and strategic delivery. He partners with IPA management to initiate, plan, design, monitor and control global projects, while ensuring they align with ImmunoPrecise’s vision.

Mr. Orloske brings a diverse background to ImmunoPrecise. Most recently, he led implementation management at WEX Health (health benefits SaaS platform), and Aldevron LLC, where he headed the North Dakota project management office. He holds a master’s degree in Project Management.

Dr. Debby Kruijsen

General Manager, Immunoprecise Antibodies Europe

View Bio

Dr. Debby Kruijsen is the General Manager of ImmunoPrecise Antibodies Europe, formerly ModiQuest Research (Oss, The Netherlands), which became part of the ImmunoPrecise family of companies in April 2018.

She began her career in immunology at Utrecht University in the Netherlands. In 2012, she joined ModiQuest Research where she held different scientific and management positions until she became General Manager of ImmunoPrecise Antibodies Europe. Dr. Kruijsen works closely with the executive and global teams to develop and execute business strategies, improve operational efficiencies, and support ImmunoPrecise as an innovative company in the CRO space.

Teri Otto

General Manager, Immunoprecise Antibodies Canada

View Bio

Teri Otto is the General Manager of ImmunoPrecise Antibodies Canada (Victoria, BC). She works closely with the executive and internal teams to implement best practices and company strategy. Ms. Otto has held a variety of scientific and management positions prior to her role as General Manager.

Teri holds a Bachelor of Science in Microbiology and Associate degrees in Psychology and Applied Chemistry/Biochemistry.

Dr. Martin Hessing

General Manager, U-Protein Express

View Bio

Dr. Martin Hessing is the General Manager and co-founder of U-Protein Express (Utrecht, The Netherlands), which became part of the ImmunoPrecise family of companies in September 2017. He has a background in Biochemistry and Hematology-Immunology from Utrecht University and held postdoc positions at Kyushu University, in Japan, and Sanquin, in Amsterdam. He obtained work and management experience at the TNO-Nutrition and Food Research Institute as well as at Organon Teknika (now Biomerieux). In 2000, he co-founded AM-Pharma BV, a biopharmaceutical company specializing in anti-infectives and sepsis. In addition, Dr. Hessing was co-founder of BiOrion BV, Microdish, SERPINx and U-PACT, and served in a number of other biotech start-up companies in various roles. He is co-author of over 50 peer-reviewed papers and seven patent applications.

Board of Directors

James Kuo, MD, MBA

Chairman

Committee Served: Finance

View Bio

Dr. James Kuo brings considerable global life science leadership, business development and financing experience to ImmunoPrecise. Currently, he serves as Managing Director of Athena Bioventures. He has been Chief Executive Officer of BioMicro Systems and Discovery Laboratories. In addition, Dr. Kuo has headed business development at Myriad Genetics and was Associate Director of Corporate Licensing and Development at Pfizer. He has further served as Managing Director of HealthCare Ventures, a $378 million venture capital fund. He is a founder and Chairman of Monarch Labs, a medical device company commercializing a wound care therapy. Dr. Kuo received his MD from the University of Pennsylvania School of Medicine and his MBA from the Wharton School of Business. He received his BA in molecular biology from Haverford College.

Robert Beecroft

Founder and Director

Committee Served: Nomination

View Bio

Robert Beecroft is the founder of ImmunoPrecise and previously served as its Chief Executive Officer, Chief Technical Officer, and President. Mr. Beecroft has over 25 years’ experience in the development of innovative and proprietary methods for the production of monoclonal and polyclonal antibodies and peptides. Mr. Beecroft has a B.Sc. in Microbiology from University of Victoria and has been involved in over 15 research projects over the course of the last 25 years, and been an instructor for graduate students at the University of Victoria on the use and production of monoclonal antibodies for over 13 years. In 2015, Mr. Beecroft was the recipient of the UVic Distinguished Alumni Award for the Faculty of Science, in recognition for being the Founder of ImmunoPrecise Antibodies Ltd.

Dr. Jennifer Bath

President & CEO, Director

Committees Served: Finance & Compensation

View Bio

Jennifer Bath is the CEO and President of ImmunoPrecise Antibodies. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry, with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.

Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. Here, she headed the global sales and client relations teams, and defined business strategies by applying knowledge based on the science, technology and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.

Greg Smith

Director

Committees Served: Finance & Compensation

View Bio

Greg Smith is a seasoned capital markets veteran who held senior positions in investment banking before recently transitioning to private equity with the acquisition of one of the largest HVAC companies in Western Canada. Mr. Smith also held the position of Portfolio Manager for Phillips, Hagar & North & Executive Director, Canadian Securitization Group, CIBC World Markets in Toronto for close to ten years. Mr. Smith, currently serves as President & Director of Broadway Refrigeration & Air Conditioning Co. Ltd. and Omega Mechanical Ltd. who collectively have over 150 employees. Mr. Smith earned an MBA from Dalhousie University and is a Chartered Financial Analyst and has served in advisory positions to multiple private and public ventures. He is currently serving as Chairman of Lite Access Technologies (TSXV:LTE).

Paul Andreola

Director

Committees Served: Compensation & Nomination

View Bio

Paul Andreola has over 20 years of business development and financial markets experience including senior management, marketing, and communications roles for early stage companies. Previously in his career, Mr. Andreola was a licensed investment advisor for over ten years and has facilitated multiple early stage private and public companies in the resource and technology sectors. Mr. Andreola is currently the CEO and director of Brisio Innovations Inc. (CSE: BZI) and Ironwood Capital Corp. (TSXV: IRN.P).

Dr. Robert D. Burke

Director

Committees Served: Finance & Nomination

View Bio

Dr. Robert D. Burke is an Emeritus Professor at the University of Victoria, where he was a faculty member for over 35 years. He has a longstanding research interest in the molecular basis of cellular signaling in early embryonic development. His research involves production and characterization of antibodies and he employs them extensively with high-resolution optical imaging methods. Dr. Burke has published over 100 peer-reviewed publications and has supervised numerous trainees. He was Chair of the Department of Biochemistry and Microbiology for eight years, was on the University of Victoria Senate for twelve years, and served on numerous advisory and management committees nationally and internationally. Dr. Burke completed a BSc (Honours) and a PhD at the University of Alberta.

Brian Lundstrom

Director

View Bio

Mr. Lundstrom has over 30 years’ experience from mostly publicly traded companies with a focus on antibody therapeutics. He started his career with product and clinical development for Novo Nordisk in Europe in 1987 and moved to the US in 1993 to form a dedicated business development function. He subsequently served as business development and financing lead for publicly traded companies such as OGS (now UCB), SangStat (now Sanofi Genzyme), ACADIA and ISCO. This included SangStat’s $600M sale and integration into Genzyme in 2003.

Since 2011 Mr. Lundstrom has established global business leadership in transgenic animals for discovery of human therapeutic antibodies (www.omniab.com), first with OMT and then with Ligand Pharmaceuticals Inc. (NASDAQ:LGND) after their $178M acquisition of OMT. In parallel, Mr. Lundstrom is founder and CEO of Ligand-partner, Abvivo LLC.

James Kuo, MD, MBA

Chairman

Committee Served: Finance

Dr. James Kuo brings considerable global life science leadership, business development and financing experience to ImmunoPrecise. Currently, he serves as Managing Director of Athena Bioventures. He has been Chief Executive Officer of BioMicro Systems and Discovery Laboratories. In addition, Dr. Kuo has headed business development at Myriad Genetics and was Associate Director of Corporate Licensing and Development at Pfizer. He has further served as Managing Director of HealthCare Ventures, a $378 million venture capital fund. He is a founder and Chairman of Monarch Labs, a medical device company commercializing a wound care therapy. Dr. Kuo received his MD from the University of Pennsylvania School of Medicine and his MBA from the Wharton School of Business. He received his BA in molecular biology from Haverford College.

Robert Beecroft

Founder and Director

Committee Served: Nomination

Robert Beecroft is the founder of ImmunoPrecise and previously served as its Chief Executive Officer, Chief Technical Officer, and President. Mr. Beecroft has over 25 years’ experience in the development of innovative and proprietary methods for the production of monoclonal and polyclonal antibodies and peptides. Mr. Beecroft has a B.Sc. in Microbiology from University of Victoria, was, an instructor for graduate students at the University of Victoria on the use and production of monoclonal antibodies for over 13 years. In 2015, Mr. Beecroft was the recipient of the UVic Distinguished Alumni Award for the Faculty of Science, in recognition for his successes as the Founder of ImmunoPrecise Antibodies Ltd.

Brian Lundstrom

Director

Mr. Lundstrom has over 30 years’ experience from mostly publicly traded companies with a focus on antibody therapeutics. He started his career with product and clinical development for Novo Nordisk in Europe in 1987 and moved to the US in 1993 to form a dedicated business development function. He subsequently served as business development and financing lead for publicly traded companies such as OGS (now UCB), SangStat (now Sanofi Genzyme), ACADIA and ISCO. This included SangStat’s $600M sale and integration into Genzyme in 2003.

Since 2011, Mr. Lundstrom has established global business leadership in transgenic animals for the discovery of human therapeutic antibodies (www.omniab.com), first with OMT and then with Ligand Pharmaceuticals Inc. (NASDAQ:LGND) after their $178M acquisition of OMT. In parallel, Mr. Lundstrom is founder and CEO of Ligand-partner, Abvivo LLC.

Dr. Jennifer Bath

President & CEO, Director

Committees Served: Finance & Compensation

Jennifer Bath is the CEO and President of ImmunoPrecise Antibodies. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry, with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.

Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. Here, she headed the global client relations and high value target teams, and defined business strategies by applying knowledge based on the science, technology and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.

Greg Smith

Director

Committees Served: Finance & Compensation

Greg Smith is a seasoned capital markets veteran who held senior positions in investment banking before recently transitioning to private equity with the acquisition of one of the largest HVAC companies in Western Canada. Mr. Smith also held the position of Portfolio Manager for Phillips, Hagar & North & as well as Executive Director, Canadian Securitization Group, CIBC World Markets in Toronto for close to ten years. Mr. Smith currently serves as President & Director of Broadway Refrigeration & Air Conditioning Co. Ltd. and Omega Mechanical Ltd., which collectively have over 150 employees. Mr. Smith earned an MBA from Dalhousie University, is a Chartered Financial Analyst and has served in advisory positions to multiple private and public ventures. He is currently serving as Chairman of Lite Access Technologies (TSXV:LTE).

Paul Andreola

Director

Committees Served: Compensation & Nomination

Paul Andreola has over twenty years' of business development and financial markets experience including senior management, marketing, and communications roles for early-stage companies. Previously in his career, Mr. Andreola was a licensed investment advisor for over ten years and facilitated multiple early-stage private and public companies in the resource and technology sectors. Mr. Andreola is currently the CEO and director of Brisio Innovations Inc. (CSE: BZI) and Ironwood Capital Corp. (TSXV: IRN.P).

Dr. Robert D. Burke

Director

Committees Served: Finance & Nomination

Dr. Robert D. Burke is an Emeritus Professor at the University of Victoria, where he was a faculty member for over 35 years. He has a longstanding research interest in the molecular basis of cellular signaling in early embryonic development. His research involves production and characterization of antibodies and he employs them extensively with high-resolution optical imaging methods. Dr. Burke has published over 100 peer-reviewed publications and has supervised numerous trainees. He was Chair of the Department of Biochemistry and Microbiology for eight years, was on the University of Victoria Senate for twelve years, and served on numerous advisory and management committees nationally and internationally. Dr. Burke completed a BSc and a PhD at the University of Alberta.

Talem Therapeutics accesses the OmniAb® platform from Ligand Pharmaceuticals

VICTORIA, November 05, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces…

November 5, 2019

ImmunoPrecise Adopts Shareholder Rights Plan

VICTORIA, October 18, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces…

October 18, 2019

ImmunoPrecise Exhibiting at European Antibody Congress in Basel, October 15-19, 2019

ImmunoPrecise Antibodies will attend the Festival of Biologics held at the Congress Centre, Basel October 15-19th. The Festival of Biologics is a combination of four incredible conferences, the European…

October 14, 2019

ImmunoPrecise Strengthens Board of Directors with Antibody Business Leader, Brian Lundstrom

VICTORIA, October 3, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the…

October 3, 2019

ImmunoPrecise Antibodies Appoints Biotech Industry Executive Dr. Stefan Lang as Chief Business Officer

VICTORIA, October 1st, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the global…

October 1, 2019

ImmunoPrecise’s Talem Therapeutics Enters into an LOI with AgonOx Pharma in the Advancement of Novel, Immuno-Oncology Therapeutics

VICTORIA, September 24, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces…

September 24, 2019

Publications

As an innovator in the field of custom antibody research and development, ImmunoPrecise Antibodies products and services have been referenced in a number of peer-reviewed studies and publications.

The link below will direct you to a list of publications on Google Scholar, a web search engine that indexes scholarly literature across journals and disciplines, that reference our company, products, and services.

Google Scholar: ImmunoPrecise Antibodies

Featured Publications

Your Privacy Matters

As part of ImmunoPrecise's shared values of Innovation, Collaboration, and Ownership, we take seriously the responsibility to protect our customer's intellectual property. Data drives every decision in the laboratory, ensuring its accurate and protected at every step is crucial in the success of our customer's projects. ImmunoPrecise has taken a defense-in-depth approach through industry-leading AI-enabled security technologies to protect intellectual property, and data from policy violations, intrusion, and breaches. Security and privacy concerns can be directed to: privacy@immunoprecise.com